Repros (RPRX) Up 2%+ Following 'Statistically Significant' Androxal Data
Tweet
Share
E-mailGet Alerts RPRX Hot Sheet
Join SI Premium – FREE
Repros Therapeutics Inc. (Nasdaq: RPRX) shares up 2.6 percent in late Thursday trading after reporting that Androxal achieved statistically significant versus a placebo in ZA-203 Phase 2b clinical study of Androxal in secondary hypogonadal men with moderate to severe dysfunction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PMV Pharmaceuticals reports 46% response rate in ovarian cancer trial
- Arrowhead's plozasiran cuts pancreatitis events 78% in Phase 3 data
- Tenax shares Phase 3 LEVEL trial data at ESC Congress 2026
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
